Hydroquinone derivatives

Details Hydroquinone derivatives Hydroquinone derivatives

1999-07-30

2002-03-19

Bernhardt, Emily (Department: 1609)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Cosmetic, antiperspirant, dentifrice

C426S545000, C514S252140, C514S253010, C514S253120, C514S255030, C544S295000, C544S360000, C544S394000

Reexamination Certificate

active

06358515

ABSTRACT:

TECHNICAL FIELD
The present invention relates to a novel and useful hydroquinone derivative and intraocular pressure lowering, antihypertensive and radical scavenging compositions containing thereof as an active ingredient.
BACKGROUND ART
Previously the present inventors successfully synthesized certain novel propanol derivatives and found that those compounds are useful as antihypertensive as well as anti-glaucomatous agents (Unexamined Japanese Patent Publication H7-157455). An antihypertensive agent and a dysuria treating agent in prostatic hypertrophy have also been known both of which contain a naphthol derivative, 1-phenyl-4-[3-(naphth-1-yl-oxy)-2-hydroxy-propyl]piperazine, as an active ingredient, [Unexamined Japanese Patent Publication H3-31271]. Furthermore, certain benzylalcohol derivatives have been disclosed which have an &agr;1-adrenergic receptor blocking activity with less side effect of orthostatic hypotension, and which are useful for glaucoma and ocular hypertension [Unexamined Japanese Patent Publication H9-12563].
DISCLOSURE OF THE INVENTION
The present inventors have further investigated relating compounds to the above and their pharmacological effects, and, as a result, have successfully synthesized a group of novel hydroquinone derivatives and found that they have potent intraocular pressure lowering, antihypertensive and radical scavenging activities. The present invention has been made on the basis of these findings and through further investigation.
Thus, the present invention relates to: (1) A hydroquinone derivative represented by the following formula:
wherein B
1
and B
2
in formula (I) are the same or different and at any position on the benzene ring (when W is nitrogen, however, at any other position on the benzene ring) and each denotes a substituent selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkoxyl and carboxyl, and the substituent CH
3
is at position 2 or 3, and W are the same or different and each denotes a nitrogen or carbon atom. R
1
, R
2
, R
3
and R
4
in formula (II) are the same or different and each denotes a substituent selected from the group consisting of hydrogen, lower alkyl and lower alkoxyl, and B
1
and B
2
are as hereinbefore defined, or a pharmacologically acceptable salt thereof (hereinafter referred to as “the present compound”), and (2) intraocular pressure lowering, antihypertensive and radical scavenging compositions containing thereof


REFERENCES:
patent: 3997666 (1976-12-01), Witte et al.
patent: 4335126 (1982-06-01), Kleeman et al.
patent: 4428950 (1984-01-01), Franke et al.
patent: 4616017 (1986-10-01), Baldwin et al.
patent: 5037828 (1991-08-01), Sponer et al.
patent: 5504087 (1996-04-01), Ogata et al.
patent: 2172183 (1996-09-01), None
patent: 2300543 (1973-07-01), None
patent: 0 401 652 (1990-12-01), None
patent: 0 611 748 (1994-08-01), None
patent: 0 735 030 (1996-10-01), None
patent: 2488892 (1978-03-01), None
patent: 1451180 (1976-09-01), None
patent: 52-83479 (1977-07-01), None
patent: 57-139067 (1982-08-01), None
patent: 58-22478 (1983-09-01), None
patent: 7-157455 (1995-06-01), None
patent: 8-325241 (1996-10-01), None
Kutscher et al., Synthese von potentiellen Naftopidil-Metaboliten, Arch. Pharm. 326(10), pp.803-806, 1993.*
Engel et al., Chemistry and Pharmacology of the Non-Benzodiazepine Anxiolytic Enciprazine and Related Compounds, J. Med. Chem. 33(4), pp. 2976-2981, 1990.*
Rastogi et al. Agents Acting on the Ventral Nervous System. 14 1-(p-Alkanoylphenoxy)-3-(N-arylpiperazinyl)prpan-2-ols. A New Class of Antidepressants, J. Med. Chem. 15(3), pp. 286-291, 1993.*
“Protective Groups in Organic Chemistry” by J.F.W.McOmie, pp. 171-172, 1973.*
Scatina, J. et al: “Metabolic disposition of enciprazine, a non-benxodiazepine anxiolytic drug in rat, dog and man” Xenobiotica (1991), 21(12), 1591-604 . . . see p. 1602 fig. 7.
Kutscher, Bernhard et al.: “Synthesis of potential naftopidil metabolites” Arch. Pharm. (Weinheim, Ger.) (1993) 326(10), 803-6, 1993 see especially compound 3 and *the whole document*.
Tmej, Claudia et al: “A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance” Arch. Phar. (Weinheim, Ger.) (1998) 331(7-8), 233-240, 1998 see compound no 214627-76-6, 1-pperazineethanol, 4-(4FPhenyl)-alpha-'(4-OHphenoxy) methyl.
Niebch, G.; Locher, M.; Peter, G.; Borbe, H. O.; “Metabolic Fate of the Novel Antihypertensive Drug Naftopidil Arzneim.”, FORSCH/DRUG RES., vol. 41, No. 10 (1991), pp. 1027-1032.
Grundke, M.; Himmel, H. M.; Wetter, E.; Borbe, H. O.; Raven, U.; “Characterization of Ca2+-Antagonistic Effects of Three Metabolites of the New Antihypertensive Agent Naftopidil, (Napthyl) Hydroxy-Naftopidil, (Phenyl) Hydroxy-Naftopidil, and O-desmethyl-Naftopidil.” J. CARDIOVASC. PHARMACOLOGY, vol. 18, No. 6 (1991), pp. 918-925.

Affiliated with

Also associated with

Rating

Hydroquinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroquinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroquinone derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2888624